Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Olema Pharmaceuticals, Inc. (OLMA)
USD11.84
-0.02 (-0.13%)
US NASDAQ Healthcare Biotechnology
Address
512 2nd Street 94107
San Francisco, CA, US
San Francisco, CA, US
CEO
Sean Bohen
Website
olema.com
IPO
2020-11-19
CIK 1750284 ISIN US68062P1066
Description
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD11.84
-0.02 (-0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
2.00
Float Shares
69.16M
Free Float %
79.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.99% | -5.99% | -13.23% | -41.18% | +73.33% | -44.12% | +193.49% | +100.43% | -42.93% | -71.49% | -71.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
11.84
Low
38.00
+221.1%
Consensus
42.50
+259.1%
Median
41.50
+250.7%
High
48.00
+305.6%
DCF (Unlevered)
0.49
-95.9%
DCF (Levered)
0.54
-95.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 10 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
38.00
+221.1%
|
| Last Year | 13 |
38.08
+221.8%
|
| All Time | 16 |
36.00
+204.2%
|
Quality scores
Altman Z-Score
13.60
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+15.0% Q1'26: -44.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+48.1% Q1'26: +20.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 8 Rev. Ana. 7 EPS Ana. |
Dec 2028 7 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
2.25M
1.15M – 3.60M
|
25.40M
11.96M – 45.41M
+1,029.0% YoY
|
125.88M
120.28M – 131.49M
+395.6% YoY
|
303.80M
155.48M – 486.52M
+141.3% YoY
|
551.37M
282.18M – 882.99M
+81.5% YoY
|
| EBITDA |
-141.87M
|
-178.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-142.26M
|
-178.70M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-129.47M
est: -134.26M (+3.6%)
|
-162.45M
est: -162.45M (+0.0%)
|
-210.55M
-228.84M – -171.18M
-29.6% YoY
|
-248.92M
-268.41M – -155.02M
-18.2% YoY
|
-199.80M
-294.39M – -48.77M
+19.7% YoY
|
-82.00M
-146.12M – -29.96M
+59.0% YoY
|
50.25M
18.36M – 89.53M
+161.3% YoY
|
| SGA |
17.74M
|
21.00M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.20
est: -2.30 (+4.4%)
|
-1.87
est: -1.89 (+1.1%)
|
-2.25
-2.63 – -1.97
-18.8% YoY
|
-2.47
-3.08 – -1.78
-10.1% YoY
|
-1.93
-3.38 – -0.56
+22.0% YoY
|
-0.94
-1.68 – -0.34
+51.1% YoY
|
0.58
0.21 – 1.03
+161.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
63
Total invested
157.04M
Insider transactions (90d)
1
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kynam Capital Management GP, LLC | 40.42M | 5.00% | — | 40.42M | — | — | OO | U.S. | 2023-02-10 | ↗ |
| 2 | Kynam Capital Management, LP | 40.42M | 5.00% | — | 40.42M | — | — | IA | U.S. | 2023-02-10 | ↗ |
| 3 | Yue Tang | 40.42M | 5.00% | — | 40.42M | — | — | IN | U.S. | 2023-02-10 | ↗ |
| 4 | Paradigm BioCapital Advisors GP LLC | 7.80M | 14.30% | 7.80M | — | 7.80M | — | OO | Delaware | 2023-09-13 | ↗ |
| 5 | Paradigm BioCapital Advisors LP | 7.80M | 14.30% | 7.80M | — | 7.80M | — | PN | Delaware | 2023-09-13 | ↗ |
| 6 | Senai Asefaw, M.D. | 7.80M | 14.30% | 7.80M | — | 7.80M | — | IN | Delaware | 2023-09-13 | ↗ |
| 7 | Bain Capital Life Sciences Opportunities IV, L.P. | 7.47M | 9.99% | — | 7.47M | — | 7.47M | PN | Delaware | 2024-12-11 | ↗ |
| 8 | Paradigm BioCapital International Fund Ltd. | 6.49M | 11.90% | 6.49M | — | 6.49M | — | CO | Delaware | 2023-09-13 | ↗ |
| 9 | (1) BlackRock, Inc. | 3.26M | 6.00% | 3.19M | — | 3.26M | — | HC | Delaware | 2024-01-29 | ↗ |
| 10 | Point72 Asset Management, L.P. | 3.23M | 5.70% | — | 3.23M | — | — | PN | Delaware | 2024-06-14 | ↗ |
| 11 | Point72 Capital Advisors, Inc. | 3.23M | 5.70% | — | 3.23M | — | — | CO | Delaware | 2024-06-14 | ↗ |
| 12 | Steven A. Cohen | 3.23M | 5.70% | — | 3.23M | — | — | IN | Delaware | 2024-06-14 | ↗ |
| 13 | David Kroin | 3.04M | 5.44% | — | 3.04M | — | — | HC, IN | Delaware | 2024-03-22 | ↗ |
| 14 | Deep Track Biotechnology Master Fund, Ltd. | 3.04M | 5.44% | — | 3.04M | — | — | CO | Delaware | 2024-03-22 | ↗ |
| 15 | Deep Track Capital, LP | 3.04M | 5.44% | — | 3.04M | — | — | IA, OO | Delaware | 2024-03-22 | ↗ |
| 16 | Dr. Senai Asefaw | 2.52M | 6.20% | 2.52M | — | 2.52M | — | IN | Delaware | 2023-04-10 | ↗ |
| 17 | Fairmount Funds Management LLC | 2.11M | 5.20% | — | 2.11M | — | 2.11M | IA | Delaware | 2022-02-11 | ↗ |
| 18 | Fairmount Healthcare Fund II GP LLC | 2.03M | 5.00% | — | 2.03M | — | 2.03M | OO | Delaware | 2022-02-11 | ↗ |
| 19 | Fairmount Healthcare Fund GP LLC | 81.0K | 0.20% | — | 81.0K | — | 81.0K | OO | Delaware | 2022-02-11 | ↗ |
| 20 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2022-11-14 | ↗ |
| 21 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-11-14 | ↗ |
| 22 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2022-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
63
-149 vs prev Q
New positions
15
Closed positions
155
Increased
36
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
15.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.23M +1.2M (+100.0%) | 30.87B +30.9B (+100.0%) | 1.44% +1.440 pp | 4.18% +4.184 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 50.0K +50.0K (+100.0%) | 1.25B +1.3B (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 3 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 8.51M +1.7M (+24.3%) | 212.72M +145.7M (+217.5%) | 9.92% +1.920 pp | 16.29% +11.845 pp | USD9.58 +161.0% | 5 qtrs — |
| 4 | PARADIGM BIOCAPITAL ADVISORS LP | 7.54M +750.0K (+11.0%) | 188.60M +122.1M (+183.6%) | 8.80% +0.853 pp | 4.81% +2.922 pp | USD9.97 +150.8% | 12 qtrs — |
| 5 | JANUS HENDERSON GROUP PLC | 6.71M +3.1M (+87.1%) | 167.90M +132.8M (+378.5%) | 7.83% +3.633 pp | 0.08% +0.059 pp | USD14.38 +73.9% | 9 qtrs — |
| 6 | BLACKROCK, INC. | 5.56M +836.9K (+17.7%) | 139.08M +92.8M (+200.6%) | 6.49% +0.961 pp | 0.00% +0.002 pp | USD12.73 +96.4% | 6 qtrs — |
| 7 | BVF INC/IL | 5.30M +— (+0.0%) | 132.40M +80.6M (+155.4%) | 6.18% -0.017 pp | 4.46% +2.355 pp | USD37.98 -34.2% | 21 qtrs — |
| 8 | FMR LLC | 5.02M +5.0M (+16,972.6%) | 125.58M +125.3M (+43,496.4%) | 5.86% +5.825 pp | 0.01% +0.006 pp | USD24.88 +0.5% | 21 qtrs — |
| 9 | VANGUARD GROUP INC | 3.56M +364.0K (+11.4%) | 89.03M +57.7M (+184.4%) | 4.15% +0.414 pp | 0.00% +0.001 pp | USD18.75 +33.3% | 21 qtrs — |
| 10 | SIREN, L.L.C. | 3.30M +3.3M (+100.0%) | 82.52M +82.5M (+100.0%) | 3.85% +3.850 pp | 2.46% +2.461 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 11 | LOGOS GLOBAL MANAGEMENT LP | 3.21M +— (+0.0%) | 80.22M +48.8M (+155.4%) | 3.74% -0.010 pp | 4.85% +2.032 pp | USD43.11 -42.0% | 21 qtrs — |
| 12 | CORMORANT ASSET MANAGEMENT, LP | 2.75M +2.8M (+100.0%) | 68.75M +68.8M (+100.0%) | 3.21% +3.208 pp | 3.18% +3.179 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 13 | RA CAPITAL MANAGEMENT, L.P. | 2.60M +2.6M (+100.0%) | 65.00M +65.0M (+100.0%) | 3.03% +3.033 pp | 0.67% +0.666 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 14 | FRANKLIN RESOURCES INC | 2.48M -535.3K (-17.8%) | 61.92M +32.4M (+110.0%) | 2.89% -0.634 pp | 0.02% +0.008 pp | USD3.98 +528.1% | 10 qtrs — |
| 15 | LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 1.93M +— (+0.0%) | 48.27M +29.4M (+155.4%) | 2.25% -0.006 pp | 3.46% -2.414 pp | USD5.83 +328.8% | 5 qtrs — |
| 16 | STATE STREET CORP | 1.88M +790.8K (+72.3%) | 47.11M +36.4M (+340.0%) | 2.20% +0.919 pp | 0.00% +0.001 pp | USD16.30 +53.4% | 20 qtrs — |
| 17 | VESTAL POINT CAPITAL, LP | 1.65M +1.7M (+100.0%) | 41.25M +41.3M (+100.0%) | 1.92% +1.925 pp | 1.40% +1.403 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 18 | WOODLINE PARTNERS LP | 1.48M -736.0K (-33.2%) | 37.05M +15.3M (+70.6%) | 1.73% -0.866 pp | 0.14% +0.041 pp | USD6.73 +271.5% | 11 qtrs — |
| 19 | POLAR CAPITAL HOLDINGS PLC | 1.38M +1.4M (+100.0%) | 34.51M +34.5M (+100.0%) | 1.61% +1.610 pp | 0.13% +0.133 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 20 | GEODE CAPITAL MANAGEMENT, LLC | 1.26M -18.6K (-1.5%) | 31.44M +18.9M (+151.6%) | 1.47% -0.026 pp | 0.00% +0.001 pp | USD12.26 +103.9% | 21 qtrs — |
| 21 | CITADEL ADVISORS LLC | 1.20M -36.6K (-3.0%) | 30.01M +17.9M (+147.8%) | 1.40% -0.047 pp | 0.00% +0.003 pp | USD10.40 +140.4% | 21 qtrs — |
| 22 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.10M +1.1M (+3,348.7%) | 27.40M +27.1M (+8,682.7%) | 1.28% +1.241 pp | 0.00% +0.003 pp | USD24.50 +2.0% | 20 qtrs — |
| 23 | SAMLYN CAPITAL, LLC | 1.07M +1.1M (+100.0%) | 26.74M +26.7M (+100.0%) | 1.25% +1.248 pp | 0.43% +0.426 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 24 | JENNISON ASSOCIATES LLC | 964.0K +964.0K (+100.0%) | 24.10M +24.1M (+100.0%) | 1.12% +1.124 pp | 0.01% +0.015 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 25 | DIMENSIONAL FUND ADVISORS LP | 958.6K -105.9K (-9.9%) | 23.97M +13.5M (+130.0%) | 1.12% -0.127 pp | 0.01% +0.003 pp | USD8.77 +185.1% | 14 qtrs — |
| 26 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 953.6K +99.6K (+11.7%) | 23.84M +15.5M (+185.1%) | 1.11% +0.113 pp | 2.83% +1.796 pp | USD11.38 +119.7% | 2 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 817.9K +14.0K (+1.7%) | 20.45M +12.6M (+159.8%) | 0.95% +0.014 pp | 0.00% +0.002 pp | USD8.77 +185.1% | 21 qtrs — |
| 28 | IKARIAN CAPITAL, LLC | 758.7K +758.7K (+100.0%) | 18.97M +19.0M (+100.0%) | 0.88% +0.885 pp | 1.48% +1.481 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 29 | CANDRIAM S.C.A. | 679.5K -570.2K (-45.6%) | 16.99M +4.8M (+38.8%) | 0.79% -0.669 pp | 0.08% +0.021 pp | USD11.02 +126.9% | 9 qtrs — |
| 30 | VIVO CAPITAL, LLC | 671.8K -834.0K (-55.4%) | 16.80M +2.1M (+13.9%) | 0.78% -0.978 pp | 1.09% -0.101 pp | USD30.50 -18.0% | 21 qtrs — |
| 31 | MORGAN STANLEY | 665.8K -890.1K (-57.2%) | 16.65M +1.4M (+9.3%) | 0.78% -1.043 pp | 0.00% +0.000 pp | USD5.71 +337.8% | 21 qtrs — |
| 32 | FIRST TURN MANAGEMENT, LLC | 617.7K +617.7K (+100.0%) | 15.44M +15.4M (+100.0%) | 0.72% +0.721 pp | 1.76% +1.765 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 33 | EVENTIDE ASSET MANAGEMENT, LLC | 569.0K +569.0K (+100.0%) | 14.23M +14.2M (+100.0%) | 0.66% +0.664 pp | 0.22% +0.222 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 34 | HOLOCENE ADVISORS, LP | 506.0K +506.0K (+100.0%) | 12.65M +12.7M (+100.0%) | 0.59% +0.590 pp | 0.03% +0.027 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 35 | PICTET ASSET MANAGEMENT HOLDING SA | 502.6K -1.1M (-69.3%) | 12.60M -3.4M (-21.4%) | 0.59% -1.328 pp | 0.01% -0.003 pp | USD11.24 +122.4% | 6 qtrs — |
| 36 | MILLENNIUM MANAGEMENT LLC | 498.5K +167.0K (+50.4%) | 12.46M +9.2M (+284.1%) | 0.58% +0.194 pp | 0.01% +0.004 pp | USD12.26 +103.9% | 17 qtrs — |
| 37 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 488.9K +488.9K (+100.0%) | 12.22M +12.2M (+100.0%) | 0.57% +0.570 pp | 0.00% +0.001 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 38 | HENNION & WALSH ASSET MANAGEMENT, INC. | 447.0K +203.0K (+83.2%) | 11.18M +8.8M (+367.7%) | 0.52% +0.236 pp | 0.39% +0.299 pp | USD15.80 +58.2% | 7 qtrs — |
| 39 | NORTHERN TRUST CORP | 445.3K -37.7K (-7.8%) | 11.13M +6.4M (+135.4%) | 0.52% -0.046 pp | 0.00% +0.001 pp | USD11.23 +122.6% | 21 qtrs — |
| 40 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 407.1K +12.0K (+3.0%) | 10.18M +6.3M (+163.1%) | 0.47% +0.013 pp | 0.00% +0.001 pp | USD10.88 +129.8% | 20 qtrs — |
| 41 | TWO SIGMA INVESTMENTS, LP | 393.7K +284.1K (+259.4%) | 9.84M +8.8M (+817.8%) | 0.46% +0.331 pp | 0.01% +0.012 pp | USD20.69 +20.8% | 18 qtrs — |
| 42 | MARSHALL WACE, LLP | 360.4K +360.4K (+100.0%) | 9.01M +9.0M (+100.0%) | 0.42% +0.420 pp | 0.01% +0.008 pp | USD25.00 +0.0% | 18 qtrs — |
| 43 | SQUAREPOINT OPS LLC | 328.7K +314.6K (+2,232.6%) | 8.22M +8.1M (+5,856.5%) | 0.38% +0.367 pp | 0.01% +0.009 pp | USD24.20 +3.3% | 9 qtrs — |
| 44 | POINT72 ASSET MANAGEMENT, L.P. | 307.9K +62.5K (+25.5%) | 7.70M +5.3M (+220.4%) | 0.36% +0.072 pp | 0.01% +0.005 pp | USD12.88 +94.1% | 7 qtrs — |
| 45 | UBS GROUP AG | 293.6K -897.1K (-75.3%) | 7.34M -4.3M (-37.0%) | 0.34% -1.050 pp | 0.00% -0.001 pp | USD4.99 +401.0% | 14 qtrs — |
| 46 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 281.7K +281.7K (+100.0%) | 7.04M +7.0M (+100.0%) | 0.33% +0.329 pp | 0.03% +0.028 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 47 | BIRCHVIEW CAPITAL, LP | 269.0K +95.0K (+54.6%) | 6.73M +5.0M (+294.8%) | 0.31% +0.110 pp | 3.94% +2.651 pp | USD12.41 +101.5% | 3 qtrs — |
| 48 | JPMORGAN CHASE & CO | 268.5K +238.3K (+791.0%) | 6.71M +6.4M (+2,175.3%) | 0.31% +0.278 pp | 0.00% +0.000 pp | USD23.12 +8.1% | 21 qtrs — |
| 49 | CATALIO CAPITAL MANAGEMENT, LP | 267.1K +267.1K (+100.0%) | 6.68M +6.7M (+100.0%) | 0.31% +0.312 pp | 1.18% +1.180 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 50 | HIGHVISTA STRATEGIES LLC | 241.5K -195.7K (-44.8%) | 6.04M +1.8M (+41.1%) | 0.28% -0.230 pp | 1.55% +0.506 pp | USD8.58 +191.4% | 11 qtrs — |
| 51 | BANK OF AMERICA CORP /DE/ | 238.9K -563.4K (-70.2%) | 5.97M -1.9M (-24.0%) | 0.28% -0.660 pp | 0.00% 0.000 pp | USD8.32 +200.5% | 21 qtrs — |
| 52 | NUVEEN, LLC | 229.5K +101.2K (+79.0%) | 5.74M +4.5M (+357.0%) | 0.27% +0.118 pp | 0.00% +0.001 pp | USD13.13 +90.4% | 4 qtrs — |
| 53 | WELLINGTON MANAGEMENT GROUP LLP | 221.0K +16.8K (+8.2%) | 5.52M +3.5M (+176.3%) | 0.26% +0.019 pp | 0.00% +0.001 pp | USD10.40 +140.4% | 11 qtrs — |
| 54 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 210.0K +210.0K (+100.0%) | 5.25M +5.3M (+100.0%) | 0.24% +0.245 pp | 0.01% +0.008 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 55 | SILVERARC CAPITAL MANAGEMENT, LLC | 206.3K -727.3K (-77.9%) | 5.16M -4.0M (-43.6%) | 0.24% -0.851 pp | 0.72% -0.516 pp | USD9.79 +155.4% | 2 qtrs — |
| 56 | AMERIPRISE FINANCIAL INC | 204.6K -942.4K (-82.2%) | 5.12M -6.1M (-54.4%) | 0.24% -1.103 pp | 0.00% -0.001 pp | USD6.42 +289.4% | 11 qtrs — |
| 57 | BANK OF NEW YORK MELLON CORP | 176.2K +7.0K (+4.1%) | 4.41M +2.7M (+165.9%) | 0.21% +0.008 pp | 0.00% +0.001 pp | USD10.54 +137.2% | 20 qtrs — |
| 58 | BALYASNY ASSET MANAGEMENT L.P. | 167.3K -525.9K (-75.9%) | 4.18M -2.6M (-38.4%) | 0.20% -0.616 pp | 0.01% -0.003 pp | USD9.79 +155.4% | 6 qtrs — |
| 59 | PERCEPTIVE ADVISORS LLC | 165.7K +165.7K (+100.0%) | 4.14M +4.1M (+100.0%) | 0.19% +0.193 pp | 0.07% +0.074 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 60 | INVESCO LTD. | 155.7K +31.1K (+25.0%) | 3.89M +2.7M (+219.1%) | 0.18% +0.036 pp | 0.00% +0.000 pp | USD10.42 +139.9% | 11 qtrs — |
| 61 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 150.7K +150.7K (+100.0%) | 3.77M +3.8M (+100.0%) | 0.18% +0.176 pp | 0.03% +0.030 pp | USD25.00 +0.0% | 6 qtrs — |
| 62 | CITIGROUP INC | 147.4K +126.9K (+620.7%) | 3.68M +3.5M (+1,740.5%) | 0.17% +0.148 pp | 0.00% +0.002 pp | USD22.36 +11.8% | 21 qtrs — |
| 63 | PIER CAPITAL, LLC | 140.1K -384.1K (-73.3%) | 3.50M -1.6M (-31.8%) | 0.16% -0.450 pp | 0.56% -0.243 pp | USD4.45 +461.8% | 5 qtrs — |
| 64 | TD ASSET MANAGEMENT INC | 136.4K +136.4K (+100.0%) | 3.41M +3.4M (+100.0%) | 0.16% +0.159 pp | 0.00% +0.003 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 65 | BARCLAYS PLC | 133.1K +38.2K (+40.3%) | 3.33M +2.2M (+193.7%) | 0.16% +0.044 pp | 0.00% +0.001 pp | USD13.80 +81.2% | 16 qtrs — |
| 66 | BURKEHILL GLOBAL MANAGEMENT, LP | 125.0K +125.0K (+100.0%) | 3.13M +3.1M (+100.0%) | 0.15% +0.146 pp | 0.21% +0.206 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 67 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 121.3K +— (+0.0%) | 3.03M +1.8M (+155.4%) | 0.14% 0.000 pp | 0.05% +0.028 pp | USD4.21 +493.8% | 4 qtrs — |
| 68 | SCHONFELD STRATEGIC ADVISORS LLC | 114.0K +114.0K (+100.0%) | 2.85M +2.8M (+100.0%) | 0.13% +0.133 pp | 0.01% +0.013 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 69 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 108.0K +108.0K (+100.0%) | 2.70M +2.7M (+100.0%) | 0.13% +0.126 pp | 0.03% +0.030 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 70 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 102.3K +81.8K (+398.1%) | 2.56M +2.4M (+1,174.9%) | 0.12% +0.095 pp | 0.00% +0.002 pp | USD21.58 +15.8% | 11 qtrs — |
| 71 | JUMP FINANCIAL, LLC | 100.3K +100.3K (+100.0%) | 2.51M +2.5M (+100.0%) | 0.12% +0.117 pp | 0.03% +0.031 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 72 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 98.2K +98.2K (+100.0%) | 2.46M +2.5M (+100.0%) | 0.11% +0.115 pp | 0.13% +0.126 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 73 | DIADEMA PARTNERS LP | 96.1K +5.6K (+6.2%) | 2.40M +1.5M (+171.2%) | 0.11% +0.006 pp | 0.41% +0.187 pp | USD10.68 +134.1% | 2 qtrs — |
| 74 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 94.9K +— (+0.0%) | 2.37M +1.4M (+155.4%) | 0.11% 0.000 pp | 0.08% +0.045 pp | USD3.89 +542.7% | 5 qtrs — |
| 75 | AMERICAN CENTURY COMPANIES INC | 93.9K +34.9K (+59.2%) | 2.35M +1.8M (+306.5%) | 0.11% +0.041 pp | 0.00% +0.001 pp | USD14.69 +70.2% | 11 qtrs — |
| 76 | JANE STREET GROUP, LLC | 88.9K +75.9K (+583.8%) | 2.22M +2.1M (+1,646.3%) | 0.10% +0.089 pp | 0.00% +0.000 pp | USD22.78 +9.7% | 2 qtrs — |
| 77 | VICTORY CAPITAL MANAGEMENT INC | 86.1K -2.1K (-2.3%) | 2.15M +1.3M (+149.4%) | 0.10% -0.003 pp | 0.00% +0.001 pp | USD13.16 +90.0% | 10 qtrs — |
| 78 | WELLS FARGO & COMPANY/MN | 84.1K +38.5K (+84.2%) | 2.10M +1.7M (+370.5%) | 0.10% +0.045 pp | 0.00% +0.000 pp | USD15.60 +60.3% | 21 qtrs — |
| 79 | ADAR1 CAPITAL MANAGEMENT, LLC | 81.4K +45.2K (+124.9%) | 2.03M +1.7M (+474.2%) | 0.09% +0.053 pp | 0.15% +0.116 pp | USD18.24 +37.1% | 2 qtrs — |
| 80 | AQR CAPITAL MANAGEMENT LLC | 81.2K -14.0 (0.0%) | 2.03M +1.2M (+155.3%) | 0.09% 0.000 pp | 0.00% +0.001 pp | USD3.98 +528.1% | 4 qtrs — |
| 81 | RHUMBLINE ADVISERS | 74.4K -9.9K (-11.8%) | 1.86M +1.0M (+125.3%) | 0.09% -0.012 pp | 0.00% +0.001 pp | USD8.22 +204.1% | 11 qtrs — |
| 82 | SOLEUS CAPITAL MANAGEMENT, L.P. | 69.9K -550.0K (-88.7%) | 1.75M -4.3M (-71.2%) | 0.08% -0.644 pp | 0.06% -0.241 pp | USD9.79 +155.4% | 2 qtrs — |
| 83 | SG AMERICAS SECURITIES, LLC | 69.4K +69.4K (+100.0%) | 1.74M +1.7M (+100.0%) | 0.08% +0.081 pp | 0.00% +0.002 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 84 | HARVEST INVESTMENT SERVICES, LLC | 68.7K +68.7K (+100.0%) | 1.72M +1.7M (+100.0%) | 0.08% +0.080 pp | 0.32% +0.324 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 85 | NICHOLAS INVESTMENT PARTNERS, LP | 64.8K +64.8K (+100.0%) | 1.62M +1.6M (+100.0%) | 0.08% +0.076 pp | 0.12% +0.118 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 86 | CREATIVE PLANNING | 64.7K +9.3K (+16.9%) | 1.62M +1.1M (+198.5%) | 0.08% +0.011 pp | 0.00% +0.001 pp | USD10.32 +142.2% | 3 qtrs — |
| 87 | ALPS ADVISORS INC | 64.6K +32.1K (+98.7%) | 1.61M +1.3M (+407.4%) | 0.08% +0.037 pp | 0.01% +0.008 pp | USD18.80 +33.0% | 9 qtrs — |
| 88 | FRED ALGER MANAGEMENT, LLC | 64.5K +64.5K (+100.0%) | 1.61M +1.6M (+100.0%) | 0.08% +0.075 pp | 0.01% +0.006 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 89 | DEUTSCHE BANK AG\ | 63.1K +2.0K (+3.2%) | 1.58M +978.6K (+163.6%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD9.70 +157.7% | 20 qtrs — |
| 90 | ALLIANCEBERNSTEIN L.P. | 62.6K -14.1K (-18.3%) | 1.57M +814.7K (+108.6%) | 0.07% -0.017 pp | 0.00% +0.000 pp | USD6.95 +259.7% | 10 qtrs — |
| 91 | QUANTINNO CAPITAL MANAGEMENT LP | 61.3K +21.0K (+52.0%) | 1.53M +1.1M (+288.2%) | 0.07% +0.024 pp | 0.00% +0.002 pp | USD14.99 +66.8% | 2 qtrs — |
| 92 | LPL FINANCIAL LLC | 56.2K -40.5K (-41.9%) | 1.40M +458.4K (+48.4%) | 0.07% -0.048 pp | 0.00% +0.000 pp | USD5.69 +339.4% | 4 qtrs — |
| 93 | SWEDBANK AB | 55.1K +55.1K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.06% +0.064 pp | 0.00% +0.001 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 94 | BOOTHBAY FUND MANAGEMENT, LLC | 55.0K +55.0K (+100.0%) | 1.38M +1.4M (+100.0%) | 0.06% +0.064 pp | 0.02% +0.021 pp | USD25.00 +0.0% | 1 qtrs NEW |
| 95 | ACT CAPITAL MANAGEMENT, LLC | 53.5K +53.5K (+100.0%) | 1.34M +1.3M (+100.0%) | 0.06% +0.062 pp | 1.08% +1.082 pp | USD25.00 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 96 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.74% | 427.5K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.53% | 1.14M | 0.50% |
| 3 | Tema Oncology ETF CANC | 0.49% | 702.4K | 0.75% |
| 4 | Fidelity Disruptive Medicine ETF FMED | 0.37% | 174.0K | 0.50% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.30% | 108.0K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.30% | 32.45M | 0.35% |
| 7 | iShares Micro-Cap ETF IWC | 0.21% | 3.12M | 0.60% |
| 8 | Vanguard Global Momentum Factor ETF VMO.TO | 0.11% | 383.7K | 0.38% |
| 9 | Vanguard U.S. Momentum Factor ETF VFMO | 0.09% | 1.45M | 0.13% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.07% | 54.2K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
27.1K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+27,061
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Raman Prakash | Director | A-Award | A | Stock Option (Right to Buy) | 24,150 | 14.59 | 352.3K | 24,150 | D | ↗ |
| 2026-03-04 | Mitchell Shawnte | Officer | M-Exempt | A | Common Stock | 25,000 | 4.37 | 109.3K | 25,000 | D | ↗ |
| 2026-03-03 | Mitchell Shawnte | Officer | M-Exempt | A | Common Stock | 15,000 | 4.37 | 65.6K | 15,000 | D | ↗ |
| 2026-02-02 | Zojwalla Naseem | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 25.65 | 6.41M | 250,000 | D | ↗ |
| 2026-02-02 | Myles David C. | Officer | A-Award | A | Performance Stock Options (Right to Buy) | 106,250 | 25.65 | 2.73M | 106,250 | D | ↗ |
| 2026-02-02 | Mitchell Shawnte | Officer | A-Award | A | Performance Stock Options (Right to Buy) | 56,250 | 25.65 | 1.44M | 56,250 | D | ↗ |
| 2026-02-02 | Bohen Sean | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 850,000 | 25.65 | 21.80M | 850,000 | D | ↗ |
| 2026-02-02 | Austin Sasha Lu | Officer | A-Award | A | Common Stock | 11,700 | 0.00 | — | 16,188 | D | ↗ |
| 2026-02-01 | Austin Sasha Lu | Officer | — | — | Stock Option (Right to Buy) | 13,000 | 2.44 | 31.7K | 0 | D | ↗ |
| 2026-01-30 | Austin Sasha Lu | Officer | — | — | Stock Option (Right to Buy) | 45,000 | 4.37 | 196.7K | 0 | D | ↗ |
| 2026-01-20 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 10,000 | 26.88 | 268.8K | 727,770 | D | ↗ |
| 2026-01-15 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 100,000 | 28.73 | 2.87M | 139,727 | D | ↗ |
| 2026-01-14 | Myles David C. | Officer | S-Sale | D | Common Stock | 35,003 | 28.99 | 1.01M | 542,761 | D | ↗ |
| 2026-01-14 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 3,489 | 29.12 | 101.6K | 737,770 | D | ↗ |
| 2026-01-13 | Myles David C. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,000 | 4.87 | 243.5K | 100,000 | D | ↗ |
| 2026-01-13 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 3,822 | 28.01 | 107.1K | 239,727 | D | ↗ |
| 2026-01-12 | Myles David C. | Officer | S-Sale | D | Common Stock | 10,000 | 28.34 | 283.4K | 144,846 | I | ↗ |
| 2025-12-26 | Bohen Sean | Director / Officer | G-Gift | D | Common Stock | 8,500 | 0.00 | — | 237,650 | D | ↗ |
| 2025-12-23 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 99,509 | 27.66 | 2.75M | 4,488 | D | ↗ |
| 2025-12-22 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 100,000 | 28.04 | 2.80M | 53,997 | D | ↗ |
| 2025-12-22 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 2,881 | 28.53 | 82.2K | 741,259 | D | ↗ |
| 2025-12-19 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 12,921 | 28.93 | 373.8K | 103,997 | D | ↗ |
| 2025-12-19 | Myles David C. | Officer | S-Sale | D | Common Stock | 6,046 | 31.39 | 189.8K | 551,881 | D | ↗ |
| 2025-12-19 | CLARK IAN T | Director | M-Exempt | D | Stock Option (Right to Buy) | 21,520 | 3.61 | 77.7K | 0 | D | ↗ |
| 2025-12-08 | Kovacs Shane William Charles | Officer | G-Gift | D | Common Stock | 75,000 | 0.00 | — | 243,549 | D | ↗ |
| 2025-11-26 | Kovacs Shane William Charles | Officer | G-Gift | D | Common Stock | 225,000 | 0.00 | — | 318,549 | D | ↗ |
| 2025-11-25 | RAPPAPORT ANDREW | Director | G-Gift | D | Common Stock | 35,868 | 0.00 | — | 0 | D | ↗ |
| 2025-11-21 | RAPPAPORT ANDREW | Director | M-Exempt | D | Stock Option (right to buy) | 35,868 | 0.39 | 14.0K | 0 | D | ↗ |
| 2025-09-18 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 10,000 | 8.33 | 83.3K | 744,140 | D | ↗ |
| 2025-09-16 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 10,000 | 8.04 | 80.4K | 754,140 | D | ↗ |
| 2025-06-11 | RAPPAPORT ANDREW | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Larson Yi | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Horning Sandra | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Harmon Cyrus | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Graham G. Walmsley | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | Garland J. Scott | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | CLARK IAN T | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-06-11 | BVF PARTNERS L P/IL | Director | A-Award | A | Stock Option (Right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | I | ↗ |
| 2025-06-11 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 24,150 | 4.08 | 98.5K | 24,150 | D | ↗ |
| 2025-02-28 | Zojwalla Naseem | Officer | A-Award | A | Stock Option (Right to Buy) | 205,000 | 4.37 | 895.9K | 205,000 | D | ↗ |
| 2025-02-28 | Myles David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 205,000 | 4.37 | 895.9K | 205,000 | D | ↗ |
| 2025-02-28 | Mitchell Shawnte | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 4.37 | 1.97M | 450,000 | D | ↗ |
| 2025-02-28 | Kovacs Shane William Charles | Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 4.37 | 1.40M | 320,000 | D | ↗ |
| 2025-02-28 | Bohen Sean | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 4.37 | 2.84M | 650,000 | D | ↗ |
| 2025-02-18 | Mitchell Shawnte | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-10 | Bain Capital Life Sciences Investors, LLC | 10% Owner | J-Other | D | Common Stock | 3,500,000 | 0.00 | — | 4,300,000 | I | ↗ |
| 2025-01-10 | BVF PARTNERS L P/IL | Director | A-Award | A | Pre-Funded Warrant | 235,450 | 0.00 | 23.55 | 3,291,004 | D | ↗ |
| 2025-01-08 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,500,000 | I | ↗ |
| 2024-12-17 | Graham G. Walmsley | Director | S-Sale | D | Common Stock | 700,761 | 6.75 | 4.73M | 0 | I | ↗ |
| 2024-12-16 | Zojwalla Naseem | Officer | M-Exempt | A | Common Stock | 14,000 | 4.87 | 68.2K | 129,509 | D | ↗ |
| 2024-12-13 | Graham G. Walmsley | Director | S-Sale | D | Common Stock | 700,761 | 6.75 | 4.73M | 0 | I | ↗ |
| 2024-12-11 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 320 | 9.39 | 3.0K | 115,509 | D | ↗ |
| 2024-12-11 | Myles David C. | Officer | S-Sale | D | Common Stock | 13,314 | 8.66 | 115.3K | 598,633 | D | ↗ |
| 2024-12-11 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 406 | 9.39 | 3.8K | 543,549 | D | ↗ |
| 2024-12-11 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 179 | 9.39 | 1.7K | 764,140 | D | ↗ |
| 2024-12-11 | Bohen Sean | Director / Officer | S-Sale | D | Common Stock | 1,267 | 9.39 | 11.9K | 241,662 | D | ↗ |
| 2024-12-10 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 13,283 | 9.37 | 124.5K | 130,031 | D | ↗ |
| 2024-12-10 | Myles David C. | Officer | S-Sale | D | Common Stock | 12,452 | 9.38 | 116.8K | 611,947 | D | ↗ |
| 2024-12-10 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 16,803 | 9.37 | 157.4K | 561,905 | D | ↗ |
| 2024-12-10 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 8,256 | 9.37 | 77.4K | 772,277 | D | ↗ |
| 2024-12-10 | Bohen Sean | Director / Officer | S-Sale | D | Common Stock | 52,328 | 9.37 | 490.3K | 298,836 | D | ↗ |
| 2024-12-09 | Zojwalla Naseem | Officer | A-Award | A | Common Stock | 52,000 | 0.00 | — | 143,314 | D | ↗ |
| 2024-12-09 | Myles David C. | Officer | A-Award | A | Common Stock | 48,750 | 0.00 | — | 624,399 | D | ↗ |
| 2024-12-09 | Kovacs Shane William Charles | Officer | A-Award | A | Common Stock | 68,250 | 0.00 | — | 578,708 | D | ↗ |
| 2024-12-09 | Harmon Cyrus | Director | A-Award | A | Common Stock | 29,250 | 0.00 | — | 780,533 | D | ↗ |
| 2024-12-09 | Bohen Sean | Director / Officer | A-Award | A | Common Stock | 204,750 | 0.00 | — | 351,164 | D | ↗ |
| 2024-12-04 | Bain Capital Life Sciences Investors, LLC | 10% Owner | — | — | Pre-Funded Warrant (right to buy) | 4,513,216 | 0.00 | 451.32 | 0 | I | ↗ |
| 2024-12-04 | BVF PARTNERS L P/IL | Director | A-Award | A | Pre-Funded Warrant | 160,107 | 0.00 | 16.01 | 313,548 | D | ↗ |
| 2024-11-15 | Kovacs Shane William Charles | Officer | M-Exempt | A | Common Stock | 25,000 | 7.02 | 175.5K | 510,458 | D | ↗ |
| 2024-08-01 | Paradigm Biocapital Advisors LP | 10% Owner | S-Sale | D | Common Stock, par value $0.0001 per share | 529,501 | 14.92 | 7.90M | 783,118 | — | ↗ |
| 2024-07-30 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 934 | 15.55 | 14.5K | 751,283 | — | ↗ |
| 2024-07-29 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 4,066 | 15.58 | 63.3K | 752,217 | — | ↗ |
| 2024-07-11 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 12.26 | 61.3K | 756,283 | — | ↗ |
| 2024-06-28 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 20,000 | 10.77 | 215.4K | 761,283 | — | ↗ |
| 2024-06-14 | RAPPAPORT ANDREW | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Larson Yi | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Horning Sandra | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Harmon Cyrus | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Graham G. Walmsley | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | Garland J. Scott | Director | A-Award | A | Stock Option (Right to Buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | CLARK IAN T | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Stock Option (Right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-14 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 23,000 | 12.36 | 284.3K | 23,000 | — | ↗ |
| 2024-06-04 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 12.33 | 61.7K | 781,283 | — | ↗ |
| 2024-06-04 | Graham G. Walmsley | Director | S-Sale | D | Common Stock | 700,000 | 14.85 | 10.40M | 700,761 | — | ↗ |
| 2024-06-03 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 10.93 | 54.7K | 786,283 | — | ↗ |
| 2024-05-31 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 15,000 | 9.41 | 141.2K | 791,283 | — | ↗ |
| 2024-05-24 | Zojwalla Naseem | Officer | M-Exempt | D | Stock Option (Right to Buy) | 9,460 | 4.87 | 46.1K | 126,840 | — | ↗ |
| 2024-05-06 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 10.92 | 54.6K | 806,283 | — | ↗ |
| 2024-04-30 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 15,000 | 9.51 | 142.7K | 811,283 | — | ↗ |
| 2024-03-28 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 20,000 | 10.97 | 219.4K | 826,283 | — | ↗ |
| 2024-03-18 | Zojwalla Naseem | Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,700 | 4.87 | 66.7K | 136,300 | — | ↗ |
| 2024-03-05 | RAPPAPORT ANDREW | Director | J-Other | D | Common Stock | 481,014 | 0.00 | — | 0 | — | ↗ |
| 2024-02-29 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 24,900 | 12.41 | 309.0K | 846,383 | — | ↗ |
| 2024-02-01 | Zojwalla Naseem | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 15.25 | 2.97M | 195,000 | — | ↗ |
| 2024-02-01 | Myles David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 15.25 | 2.97M | 195,000 | — | ↗ |
| 2024-02-01 | Kovacs Shane William Charles | Officer | A-Award | A | Stock Option (Right to Buy) | 304,500 | 15.25 | 4.64M | 304,500 | — | ↗ |
| 2024-02-01 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 15.56 | 77.8K | 871,283 | — | ↗ |
| 2024-02-01 | Bohen Sean | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 621,500 | 15.25 | 9.48M | 621,500 | — | ↗ |
| 2024-01-31 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 25,000 | 12.23 | 305.8K | 876,283 | — | ↗ |
| 2024-01-25 | Zojwalla Naseem | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 7.02 | 140.4K | 214,000 | — | ↗ |
| 2024-01-12 | Kovacs Shane William Charles | Officer | M-Exempt | A | Common Stock | 50,000 | 7.02 | 351.0K | 484,987 | — | ↗ |
| 2023-12-29 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 22,500 | 13.30 | 299.3K | 903,783 | — | ↗ |
| 2023-12-12 | Kovacs Shane William Charles | Officer | M-Exempt | A | Common Stock | 10,000 | 7.02 | 70.2K | 434,987 | — | ↗ |
| 2023-12-11 | Zojwalla Naseem | Officer | M-Exempt | A | Common Stock | 2,900 | 7.02 | 20.4K | 46,664 | — | ↗ |
| 2023-12-07 | Zojwalla Naseem | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-06 | Zojwalla Naseem | Officer | M-Exempt | A | Common Stock | 13,100 | 7.02 | 92.0K | 43,764 | — | ↗ |
| 2023-12-06 | Paradigm Biocapital Advisors LP | 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 100,000 | 11.60 | 1.16M | 6,590,981 | — | ↗ |
| 2023-12-05 | Graham G. Walmsley | Director | P-Purchase | A | Common Stock | 50,000 | 13.09 | 654.3K | 1,800,000 | — | ↗ |
| 2023-11-30 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 25,000 | 12.57 | 314.3K | 926,283 | — | ↗ |
| 2023-11-22 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 7,095 | 13.89 | 98.5K | 30,664 | — | ↗ |
| 2023-11-22 | Myles David C. | Officer | S-Sale | D | Common Stock | 6,653 | 13.89 | 92.4K | 574,099 | — | ↗ |
| 2023-11-22 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 9,145 | 13.89 | 127.0K | 424,987 | — | ↗ |
| 2023-11-22 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 3,989 | 13.90 | 55.4K | 951,283 | — | ↗ |
| 2023-11-22 | Bohen Sean | Director / Officer | S-Sale | D | Common Stock | 27,932 | 13.90 | 388.3K | 144,925 | — | ↗ |
| 2023-11-21 | Zojwalla Naseem | Officer | S-Sale | D | Common Stock | 7,261 | 14.83 | 107.7K | 37,959 | — | ↗ |
| 2023-11-21 | Myles David C. | Officer | S-Sale | D | Common Stock | 6,776 | 14.87 | 100.8K | 580,952 | — | ↗ |
| 2023-11-21 | Kovacs Shane William Charles | Officer | S-Sale | D | Common Stock | 700 | 15.27 | 10.7K | 434,132 | — | ↗ |
| 2023-11-21 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 4,192 | 14.86 | 62.3K | 955,272 | — | ↗ |
| 2023-11-21 | Bohen Sean | Director / Officer | S-Sale | D | Common Stock | 26,691 | 14.84 | 396.1K | 175,459 | — | ↗ |
| 2023-11-20 | Zojwalla Naseem | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 45,220 | — | ↗ |
| 2023-11-20 | Myles David C. | Officer | A-Award | A | Common Stock | 26,250 | 0.00 | — | 587,728 | — | ↗ |
| 2023-11-20 | Kovacs Shane William Charles | Officer | A-Award | A | Common Stock | 36,750 | 0.00 | — | 443,729 | — | ↗ |
| 2023-11-20 | Harmon Cyrus | Director | A-Award | A | Common Stock | 15,750 | 0.00 | — | 959,464 | — | ↗ |
| 2023-11-20 | Bohen Sean | Director / Officer | A-Award | A | Common Stock | 110,250 | 0.00 | — | 202,150 | — | ↗ |
| 2023-11-08 | Myles David C. | Officer | S-Sale | D | Common Stock | 200 | 17.61 | 3.5K | 561,270 | — | ↗ |
| 2023-11-03 | Myles David C. | Officer | S-Sale | D | Common Stock | 541 | 17.51 | 9.5K | 561,470 | — | ↗ |
| 2023-11-02 | Myles David C. | Officer | S-Sale | D | Common Stock | 3,332 | 15.36 | 51.2K | 562,011 | — | ↗ |
| 2023-11-02 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 15.64 | 78.2K | 943,714 | — | ↗ |
| 2023-11-01 | Myles David C. | Officer | S-Sale | D | Common Stock | 6,668 | 15.02 | 100.2K | 565,343 | — | ↗ |
| 2023-10-31 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 25,000 | 12.05 | 301.3K | 948,714 | — | ↗ |
| 2023-10-16 | Garland J. Scott | Director | A-Award | A | Stock Option (Right to Buy) | 21,520 | 10.54 | 226.8K | 21,520 | — | ↗ |
| 2023-09-29 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 25,000 | 12.41 | 310.3K | 973,714 | — | ↗ |
| 2023-09-19 | Myles David C. | Officer | S-Sale | D | Common Stock | 20,000 | 12.67 | 253.4K | 572,011 | — | ↗ |
| 2023-09-14 | BVF PARTNERS L P/IL | Director / 10% Owner | J-Other | A | Common stock, $0.0001 par value | 99,556 | 0.00 | — | 99,556 | — | ↗ |
| 2023-09-12 | Paradigm Biocapital Advisors LP | 10% Owner | — | I | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 1,312,619 | — | ↗ |
| 2023-09-12 | Graham G. Walmsley | Director | P-Purchase | A | Common Stock | 508,130 | 9.84 | 5.00M | 1,668,130 | — | ↗ |
| 2023-09-12 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common stock, $0.0001 par value | 775,278 | 9.84 | 7.63M | 4,688,954 | — | ↗ |
| 2023-09-05 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 10,000 | 11.62 | 116.2K | 998,714 | — | ↗ |
| 2023-08-31 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 15,000 | 9.36 | 140.4K | 1,008,714 | — | ↗ |
| 2023-08-16 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 15,000 | 10.14 | 152.1K | 1,023,714 | — | ↗ |
| 2023-06-16 | RAPPAPORT ANDREW | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | Larson Yi | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | Horning Sandra | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | Graham G. Walmsley | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | CLARK IAN T | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Stock Option (Right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-16 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 7.84 | 168.7K | 21,520 | — | ↗ |
| 2023-06-08 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 10,000 | 6.30 | 63.0K | 1,038,714 | — | ↗ |
| 2023-06-06 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 6.30 | 31.5K | 1,048,714 | — | ↗ |
| 2023-06-05 | Harmon Cyrus | Director | S-Sale | D | Common Stock | 5,000 | 6.05 | 30.2K | 1,053,714 | — | ↗ |
| 2023-04-06 | Kovacs Shane William Charles | Officer | P-Purchase | A | Common Stock | 10,000 | 3.42 | 34.2K | 396,197 | — | ↗ |
| 2023-02-01 | Zojwalla Naseem | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.87 | 730.5K | 150,000 | — | ↗ |
| 2023-02-01 | Myles David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.87 | 730.5K | 150,000 | — | ↗ |
| 2023-02-01 | Moriarty John B | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.87 | 730.5K | 150,000 | — | ↗ |
| 2023-02-01 | Kovacs Shane William Charles | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 4.87 | 974.0K | 200,000 | — | ↗ |
| 2023-02-01 | Horn Kinney | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.87 | 730.5K | 150,000 | — | ↗ |
| 2023-02-01 | Harmon Cyrus | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.87 | 730.5K | 150,000 | — | ↗ |
| 2023-02-01 | Bohen Sean | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 550,000 | 4.87 | 2.68M | 550,000 | — | ↗ |
| 2022-09-02 | Kovacs Shane William Charles | Officer | P-Purchase | A | Common Stock | 20,000 | 3.59 | 71.8K | 381,197 | — | ↗ |
| 2022-06-17 | RAPPAPORT ANDREW | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | Larson Yi | — | A-Award | A | Stock Option (Right to Buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | Hrustanovic Gorjan | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | Horning Sandra | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | Graham G. Walmsley | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | CLARK IAN T | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-17 | BUTITTA CYNTHIA M | — | A-Award | A | Stock Option (right to buy) | 21,520 | 3.61 | 77.7K | 21,520 | — | ↗ |
| 2022-06-16 | RAPPAPORT ANDREW | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 3.43 | 73.8K | 21,520 | — | ↗ |
| 2022-06-16 | Larson Yi | Director | A-Award | A | Stock Option (Right to Buy) | 21,520 | 0.00 | — | 21,520 | — | ↗ |
| 2022-06-16 | Hrustanovic Gorjan | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 0.00 | — | 21,520 | — | ↗ |
| 2022-06-16 | Horning Sandra | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 0.00 | — | 21,520 | — | ↗ |
| 2022-06-16 | Graham G. Walmsley | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 3.43 | 73.8K | 21,520 | — | ↗ |
| 2022-06-16 | CLARK IAN T | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 3.43 | 73.8K | 21,520 | — | ↗ |
| 2022-06-16 | BUTITTA CYNTHIA M | Director | A-Award | A | Stock Option (right to buy) | 21,520 | 0.00 | — | 21,520 | — | ↗ |
| 2022-06-10 | LAMPERT MARK N | Director | P-Purchase | A | Common stock, $0.0001 par value | 41,417 | 4.03 | 167.1K | 2,906,659 | — | ↗ |
| 2022-03-10 | Horn Kinney | Director / Officer | M-Exempt | A | Common Stock | 5,253 | 2.06 | 10.8K | 7,711 | — | ↗ |
| 2022-02-10 | Horn Kinney | — | D-Return | D | Common Stock | 5,251 | 5.46 | 28.7K | 2,458 | — | ↗ |
| 2022-02-01 | Zojwalla Naseem | — | A-Award | A | Stock Option (Right to Buy) | 250,000 | 7.02 | 1.76M | 250,000 | — | ↗ |
| 2022-02-01 | Myles David C. | — | A-Award | A | Stock Option (Right to Buy) | 118,750 | 7.02 | 833.6K | 118,750 | — | ↗ |
| 2022-02-01 | Moriarty John B | — | A-Award | A | Stock Option (Right to Buy) | 166,250 | 7.02 | 1.17M | 166,250 | — | ↗ |
| 2022-02-01 | Kushner Peter J. | — | A-Award | A | Stock Option (Right to Buy) | 61,750 | 7.02 | 433.5K | 61,750 | — | ↗ |
| 2022-02-01 | Kovacs Shane William Charles | — | A-Award | A | Stock Option (Right to Buy) | 247,000 | 7.02 | 1.73M | 247,000 | — | ↗ |
| 2022-02-01 | Horn Kinney | — | A-Award | A | Stock Option (Right to Buy) | 133,000 | 7.02 | 933.7K | 133,000 | — | ↗ |
| 2022-02-01 | Harmon Cyrus | — | A-Award | A | Stock Option (Right to Buy) | 104,500 | 7.02 | 733.6K | 104,500 | — | ↗ |
| 2022-02-01 | Bohen Sean | — | A-Award | A | Stock Option (Right to Buy) | 812,250 | 7.02 | 5.70M | 812,250 | — | ↗ |
| 2022-01-31 | Zojwalla Naseem | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-10 | Horn Kinney | — | M-Exempt | D | Stock Option (Right to Buy) | 5,251 | 2.06 | 10.8K | 152,289 | — | ↗ |
| 2021-12-10 | Myles David C. | — | S-Sale | D | Common Stock | 10,000 | 10.30 | 103.0K | 582,901 | — | ↗ |
| 2021-12-10 | Horn Kinney | — | M-Exempt | A | Common Stock | 5,251 | 2.06 | 10.8K | 7,709 | — | ↗ |
| 2021-11-30 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common stock, $0.0001 par value | 362,430 | 9.39 | 3.40M | 3,755,093 | — | ↗ |
| 2021-11-29 | Harmon Cyrus | — | S-Sale | D | Common Stock | 400 | 24.76 | 9.9K | 1,051,146 | — | ↗ |
| 2021-11-10 | Horn Kinney | — | M-Exempt | A | Common Stock | 5,251 | 2.06 | 10.8K | 7,041 | — | ↗ |
| 2021-10-19 | Harmon Cyrus | — | S-Sale | D | Common Stock | 7,445 | 27.85 | 207.3K | 1,056,101 | — | ↗ |
| 2021-10-14 | Bohen Sean | — | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 4.82 | 24.1K | 966,316 | — | ↗ |
| 2021-10-11 | Horn Kinney | — | M-Exempt | A | Common Stock | 5,251 | 2.06 | 10.8K | 7,041 | — | ↗ |
| 2021-09-27 | Bohen Sean | — | M-Exempt | D | Stock Option (Right to Buy) | 1,085 | 4.82 | 5.2K | 971,316 | — | ↗ |
| 2021-09-20 | Harmon Cyrus | — | S-Sale | D | Common Stock | 12,000 | 26.30 | 315.6K | 1,063,546 | — | ↗ |
Executive team
Top executives
Shares Outstanding
87.16M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Sean Bohen, M.D., Ph.D. President and Chief Executive Officer | 673.0K | — | — | 7.01M | 432.1K | 15.0K | 8.13M | 86.22% | ↗ |
| 2 | 2024 | Shane Kovacs Chief Operating and Financial Officer | 541.0K | — | — | 3.43M | 289.4K | 15.0K | 4.28M | 80.25% | ↗ |
| 3 | 2024 | Naseem Zojwalla, M.D. Chief Medical Officer | 515.0K | — | — | 2.20M | 248.0K | 15.0K | 2.98M | 73.87% | ↗ |
| 4 | 2023 | Sean Bohen, M.D., Ph.D. President and Chief Executive Officer | 647.0K | — | — | 2.00M | 489.0K | 14.4K | 3.15M | 63.51% | ↗ |
| 5 | 2023 | Shane Kovacs Chief Operating and Financial Officer | 520.0K | — | — | 728.0K | 286.0K | 14.4K | 1.55M | 47.02% | ↗ |
| 6 | 2023 | Cyrus Harmon, Ph.D. Former Chief Research Officer and Former Chief Executive Officer | 121.0K | — | — | 550.2K | 48.0K | 615.7K | 1.33M | 41.22% | ↗ |
| 7 | 2023 | Naseem Zojwalla, M.D. Chief Medical Officer | 477.0K | — | — | 546.0K | 262.0K | 14.4K | 1.30M | 42.02% | ↗ |
| 8 | 2022 | Sean Bohen, M.D., Ph.D. President and Chief Executive Officer | 615.8K | — | 1.06M | 3.92M | 372.6K | 13.4K | 5.99M | 83.27% | ↗ |
| 9 | 2022 | Shane Kovacs Chief Operating and Financial Officer | 495.0K | — | 354.9K | 1.19M | 217.8K | 13.4K | 2.27M | 68.07% | ↗ |
| 10 | 2022 | Naseem Zojwalla, M.D. Chief Medical Officer | 414.2K | 150.0K | 270.4K | 1.21M | 198.0K | 13.3K | 2.25M | 65.59% | ↗ |
| 11 | 2021 | Sean Bohen President and Chief Executive Officer | — | — | — | 2.32M | 392.7K | 11.6K | 33.24M | 6.99% | ↗ |
| 12 | 2021 | Sean Bohen, M.D., Ph.D. President and Chief Executive Officer | 595.0K | — | — | 2.32M | 392.7K | 11.6K | 3.32M | 69.93% | ↗ |
| 13 | 2021 | Kinney Horn Chief Business Officer | — | — | — | 1.24M | 181.7K | 11.6K | 1.83M | 67.74% | ↗ |
| 14 | 2021 | Shane Kovacs Chief Operating and Financial Officer | 470.0K | — | — | — | 220.9K | 184.7K | 875.6K | 0.00% | ↗ |
| 15 | 2020 | Sean Bohen President and Chief Executive Officer | — | — | — | 10.31M | 109.2K | — | 10.60M | 97.29% | ↗ |
| 16 | 2020 | Cyrus Harmon, Ph.D. Chief Technology Officer and former Chief Executive Officer | 395.8K | — | 344.0K | 2.97M | 262.2K | — | 3.98M | 83.45% | ↗ |
| 17 | 2020 | Peter J. Kushner, Ph.D. Chief Scientific Officer | 293.5K | — | 344.0K | 2.25M | 136.5K | — | 3.02M | 85.79% | ↗ |
| 18 | 2020 | John B. Moriarty Executive Vice President, Chief Legal Officer | 125.6K | — | — | 2.83M | 57.7K | — | 3.02M | 93.93% | ↗ |
| 19 | 2019 | Cyrus Harmon, Ph.D. Chief Technology Officer and former Chief Executive Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 20 | 2019 | Peter J. Kushner, Ph.D. Chief Scientific Officer | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean Bohen | President, CEO, Interim Principal Financial Officer & Director | 1M | — |
| Shane William Charles Kovacs | Consultant | 902.7K | male |
| Naseem Zojwalla | Chief Medical Officer | 778.0K | — |
| Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | 664.8K | female |
| David C. Myles | Chief Scientific Officer | 200.0K | — |
| Angelos Dovletoglou | Senior Vice President of CMC & Supply Chain | — | — |
| Richard Hernandez | Senior Vice President of Clinical Development Operations | — | male |
| Sasha Austin | Vice President of Finance & Controller | — | female |
| Meghna Chowdary | Senior Vice President of Commercial Strategy & Operations | — | female |
| Courtney O'Konek | Vice President of Corporate Communications | — | female |
| Julie Dexter | Senior Vice President & Head of People | — | female |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OLMA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
